Drug-related harm coinciding with income assistance payments: results from a community-based cohort of people who use drugs.
Drug use
drug-related harm
income assistance
poverty
social policy
violence
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
21
02
2020
revised:
02
04
2020
accepted:
29
06
2020
pubmed:
6
7
2020
medline:
30
9
2021
entrez:
5
7
2020
Statut:
ppublish
Résumé
Income assistance is critical to the health and wellbeing of socio-economically marginalized people who use illicit drugs (PWUD). However, past literature paradoxically identifies unintended increases in drug-related harm coinciding with synchronized payments that may magnify signals for drug use. The scope of such harm has not been fully characterized among non-institutionalized populations. This study examined socio-demographic, health and drug use-related correlates of payment-coincident drug-related harm. This observational study uses data from prospective community-based longitudinal cohorts of PWUD between December 2013 and May 2018. Vancouver, British Columbia, Canada. A total of 1604 PWUD receiving monthly income assistance. Our sample included 586 (36.5%) women, 861 (53.7%) non-white participants and 685 (42.7%) people living with HIV. The primary outcome was a self-reported composite measure of drug-related harm in the past 6 months coinciding with income assistance, including higher-frequency substance use, non-fatal overdose and service barriers or interruptions. Subanalyses disaggregated this outcome. Payment-coincident drug-related harm was reported among 77.7% of participants during the study period. In multivariable models, key correlates positively and significantly associated with payment-coincident harm included: street-based income generation [adjusted odds ratio (aOR) = 1.48, 95% confidence interval (CI) = 1.26-1.74, P < 0.001], sex work (aOR = 1.66, 95% CI = 1.35-2.04, P < 0.001), illegal income generation (aOR = 1.57, 95% CI = 1.35-1.83 P < 0.001), homelessness (aOR = 1.34, 95% CI = 1.13-1.58, P < 0.001), exposure to violence (aOR = 1.31, 95% CI = 1.03-1.66, P = 0.032), daily crack cocaine use (aOR = 1.99, 95% CI = 1.59-2.50, P < 0.001), heavy alcohol use (aOR = 1.64, 95% CI = 1.37-1.97, P < 0.001) and injection drug use (aOR = 2.55, 95% CI = 2.01-3.23, P < 0.001). In subanalyses, specific harms were more likely among individuals reporting social, structural and health vulnerabilities. In Vancouver, Canada, people who use illicit drugs who receive income assistance report high prevalence of payment-coincident drug-related harm, particularly people experiencing socioeconomic and structural marginalization or engaging in high-intensity drug use.
Sections du résumé
BACKGROUND AND AIMS
Income assistance is critical to the health and wellbeing of socio-economically marginalized people who use illicit drugs (PWUD). However, past literature paradoxically identifies unintended increases in drug-related harm coinciding with synchronized payments that may magnify signals for drug use. The scope of such harm has not been fully characterized among non-institutionalized populations. This study examined socio-demographic, health and drug use-related correlates of payment-coincident drug-related harm.
DESIGN
This observational study uses data from prospective community-based longitudinal cohorts of PWUD between December 2013 and May 2018.
SETTING
Vancouver, British Columbia, Canada.
PARTICIPANTS
A total of 1604 PWUD receiving monthly income assistance. Our sample included 586 (36.5%) women, 861 (53.7%) non-white participants and 685 (42.7%) people living with HIV.
MEASUREMENTS
The primary outcome was a self-reported composite measure of drug-related harm in the past 6 months coinciding with income assistance, including higher-frequency substance use, non-fatal overdose and service barriers or interruptions. Subanalyses disaggregated this outcome.
FINDINGS
Payment-coincident drug-related harm was reported among 77.7% of participants during the study period. In multivariable models, key correlates positively and significantly associated with payment-coincident harm included: street-based income generation [adjusted odds ratio (aOR) = 1.48, 95% confidence interval (CI) = 1.26-1.74, P < 0.001], sex work (aOR = 1.66, 95% CI = 1.35-2.04, P < 0.001), illegal income generation (aOR = 1.57, 95% CI = 1.35-1.83 P < 0.001), homelessness (aOR = 1.34, 95% CI = 1.13-1.58, P < 0.001), exposure to violence (aOR = 1.31, 95% CI = 1.03-1.66, P = 0.032), daily crack cocaine use (aOR = 1.99, 95% CI = 1.59-2.50, P < 0.001), heavy alcohol use (aOR = 1.64, 95% CI = 1.37-1.97, P < 0.001) and injection drug use (aOR = 2.55, 95% CI = 2.01-3.23, P < 0.001). In subanalyses, specific harms were more likely among individuals reporting social, structural and health vulnerabilities.
CONCLUSIONS
In Vancouver, Canada, people who use illicit drugs who receive income assistance report high prevalence of payment-coincident drug-related harm, particularly people experiencing socioeconomic and structural marginalization or engaging in high-intensity drug use.
Identifiants
pubmed: 32621376
doi: 10.1111/add.15182
pmc: PMC7779750
mid: NIHMS1621339
doi:
Substances chimiques
Illicit Drugs
0
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
536-545Subventions
Organisme : NIDA NIH HHS
ID : U01 DA038886
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA021525
Pays : United States
Organisme : CIHR
ID : FDN 154320
Pays : Canada
Organisme : CIHR
ID : MSH 141971
Pays : Canada
Organisme : CIHR
ID : MSH 217672
Pays : Canada
Organisme : CIHR
ID : MSH 360816
Pays : Canada
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 Society for the Study of Addiction.
Références
Int J Drug Policy. 2007 Jan;18(1):27-36
pubmed: 17689341
Health Place. 2010 Jan;16(1):51-60
pubmed: 19733496
Drug Alcohol Depend. 2019 Apr 1;197:49-55
pubmed: 30776571
Int J Drug Policy. 2018 Sep;59:36-43
pubmed: 29986270
AIDS. 2003 Apr 11;17(6):887-93
pubmed: 12660536
Health Aff (Millwood). 1996 Fall;15(3):192-200
pubmed: 8854526
Health Aff (Millwood). 2002 Mar-Apr;21(2):31-46
pubmed: 11900185
BMC Public Health. 2019 Jan 3;19(1):2
pubmed: 30606263
BMC Public Health. 2016 Jul 29;16:668
pubmed: 27473400
Addiction. 2011 Jun;106(6):1071-7
pubmed: 21338431
Health Place. 2015 May;33:67-74
pubmed: 25770437
Int J Drug Policy. 2014 Jul;25(4):736-9
pubmed: 24795288
Int J Drug Policy. 2018 Oct;60:40-46
pubmed: 30098498
BMJ. 2009 Apr 30;338:b1649
pubmed: 19406887
Lancet. 2008 Nov 8;372(9650):1633-40
pubmed: 18994660
J Behav Health Serv Res. 2010 Apr;37(2):252-71
pubmed: 18679805
Int J Drug Policy. 2016 Jul;33:83-7
pubmed: 27402469
BMC Health Serv Res. 2012 Jan 23;12:18
pubmed: 22270080
Milbank Q. 2005;83(1):65-99
pubmed: 15787954
N Engl J Med. 1995 Sep 21;333(12):777-83
pubmed: 7643886
Curr HIV/AIDS Rep. 2012 Dec;9(4):364-74
pubmed: 22968432
Ann Emerg Med. 1991 Jul;20(7):739-42
pubmed: 1648313
Drug Alcohol Depend. 2007 Nov 2;91(1):50-6
pubmed: 17561355
Acad Emerg Med. 1997 Feb;4(2):118-23
pubmed: 9043538
J Subst Abuse Treat. 2018 Nov;94:41-46
pubmed: 30243416
Int J Drug Policy. 2013 Sep;24(5):479-87
pubmed: 23664788
Cochrane Database Syst Rev. 2016 Sep 27;9:CD007380
pubmed: 27670244
J Epidemiol Community Health. 2015 Jul;69(7):686-92
pubmed: 25691275
Can J Psychiatry. 2015 Mar;60(3):146-50
pubmed: 25886690
Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003023
pubmed: 17636713
Am Econ Rev. 2017 May;107(5):551-5
pubmed: 29558067
Am J Public Health. 1999 May;89(5):752-5
pubmed: 10224989
Int J Drug Policy. 2009 May;20(3):193-201
pubmed: 19147339
Qual Health Res. 2011 Jun;21(6):743-56
pubmed: 21378259
Soc Sci Med. 2016 Dec;171:94-102
pubmed: 27842998
Curr Epidemiol Rep. 2014 Sep 1;1(3):149-164
pubmed: 25984439
Int J Drug Policy. 2012 Jan;23(1):3-5
pubmed: 21996164
N Engl J Med. 1999 Jul 8;341(2):93-8
pubmed: 10395634
Harm Reduct J. 2007 Apr 26;4:12
pubmed: 17462093
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Arch Gen Psychiatry. 2009 Jan;66(1):88-94
pubmed: 19124692
Addiction. 2003 Jul;98(7):965-75
pubmed: 12814502
Health Serv Res. 2000 Oct;35(4):813-23
pubmed: 11055450
Int J Drug Policy. 2014 May;25(3):608-15
pubmed: 24332972
J Health Soc Behav. 1999 Mar;40(1):79-86
pubmed: 10331323
J Urban Health. 2011 Aug;88(4):724-35
pubmed: 21533961
AIDS. 1997 Jul;11(8):F59-65
pubmed: 9223727
AIDS. 2015 Nov 28;29(18):2487-95
pubmed: 26558546
Lancet. 2015 Jan 3;385(9962):55-71
pubmed: 25059947
Lancet. 2013 Nov 9;382(9904):1564-74
pubmed: 23993281
Am J Med. 2001 Apr 1;110(5):347-51
pubmed: 11286948
AIDS Behav. 2010 Oct;14(5):1159-68
pubmed: 19466537
Psychiatr Serv. 2000 Jan;51(1):31
pubmed: 10647133
CMAJ. 2002 Sep 17;167(6):633-7
pubmed: 12358196
Exp Clin Psychopharmacol. 2014 Feb;22(1):23-34
pubmed: 24188170
Health Serv Res. 2006 Feb;41(1):173-91
pubmed: 16430606
J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):56-9
pubmed: 14707793
Lancet. 2014 Oct 25;384(9953):1529-40
pubmed: 25390578
Soc Sci Med. 2014 Jul;112:63-71
pubmed: 24814227
Psychiatr Serv. 1997 Jun;48(6):792-5
pubmed: 9175187
Public Health Rep. 2002;117 Suppl 1:S135-45
pubmed: 12435837
Lancet. 2018 Jan 20;391(10117):241-250
pubmed: 29137869